A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Eligible age
55+ yrs
Accepts
All genders
Locations
33 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Sponsor: Cleerly, Inc.
You may qualify if…
- ✓ 1. Provided electronic or written informed consent
- ✓ 2. Men \> 55, women \> 65 years of age
- ✓ 3. Type 2 diabetes mellitus requiring pharmacologic therapy or with their most recent A1c 6.5%. Patients with prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL \[5.6-6.9 mmol/L\]) and/or metabolic syndrome can be enrolled through 12 October 2026 and proceed with randomization; however, no additional participants may enroll with these criteria after this date. Metabolic syndrome is defined as \> 3 of the following criteria (International Diabetes Federation 2006):
- ✓ Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
- ✓ Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
- ✓ HDL-cholesterol (HDL-C) \< 40 mg/dL (1.03 mmol/L) in men, \<50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
- ✓ Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
- ✓ Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%
You may not qualify if…
- ✕ 1. Any one of the following:
- ✕ 1. A history of acute myocardial infarction (heart attack), stroke, or non-traumatic leg/foot/toe amputation
- ✕ 2. A history of an arterial revascularization procedure for coronary, peripheral, and/or carotid atherosclerotic disease (i.e. coronary stent or bypass, carotid stent)
- ✕ 3. Symptoms suspicious of coronary artery disease, stroke or peripheral artery disease confirmed by a diagnostic test within the last 12 months (i.e. nuclear stress test, invasive angiogram, brain MRI/CT
- ✕ 4. Asymptomatic ASCVD including treatment with therapies (e.g. antiplatelets, lipid lowering) intended to reduce CV risk due to the imaging evidence of atherosclerosis and/or management to goals consistent with secondary prevention guidelines (e.g. LDL-C \< 70 mg/dL)
- ✕ 2. Planned arterial revascularization
- ✕ 3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:
- ✕ 1. eGFR \< 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr\_calculator)
Where it's recruiting
Chandler · Scottsdale · Sun City · Tucson
Beverly Hills · Canoga Park · Chula Vista · Granada Hills …
Aurora · Denver
Boca Raton · Cross City · Hialeah · Jacksonville …
Augusta · Dunwoody · Fayetteville · Lithia Springs …
Meridian
Chicago · Glenview
Indianapolis
West Des Moines
Edgewood · Louisville
New Orleans
Bowie · Columbia
Source: ClinicalTrials.gov · NCT06112418 · last updated 2026-11-19